Peripheral opioid analgesia for the treatment of neuropathic pain: Gene mutation to virus mediated gene transfer

Sarah M. Sweitzer, Cristina E. Minella, Steven P. Wilson, Srinivasa N. Raja

Research output: Contribution to journalArticle

Abstract

Neuropathic pain can result from a number of different diseases, medical interventions and injuries. In addition to varying aetiologies, neuropathic pain may also differ in the anatomical location of the lesion - from peripheral nociceptors to the highest centres in the brain. The management of neuropathic pain continues to be a challenge for clinicians and despite taking prescribed medication for pain, patients with neuropathic pain continue to have pain of moderate severity. The use of opioids for the treatment of chronic neuropathic pain remains controversial. Recent studies demonstrate opioid analgesics are effective in neuropathic pain states but their use is often limited by unacceptable side effects that are mediated by opioid actions in the central nervous system. While it was once dogma that opioids exert their analgesic effects by binding to receptors in the central nervous system, there is a growing recognition of a potent peripheral analgesia in experimental models of inflammatory and neuropathic pains, and in clinical settings. The working model is that peripheral opioids can be used to treat neuropathic pain while avoiding the often dose-limiting and unacceptable central nervous system mediated side effects. Our work has focused on characterizing this peripheral opioid analgesia such that it can be exploited to develop novel and potent peripheral analgesics for the treatment of neuropathic pain. This article will set the clinical stage for the need for novel treatments for neuropathic pain, the use of gene mutation strategies to make the case for the use of opioids in treating neuropathic pain, the demonstration of peripheral opioid analgesia in neuropathic pain, and our work with virus mediated gene transfer to enhance peripheral opioid analgesia in neuropathic pain.

Original languageEnglish
Pages (from-to)251-256
Number of pages6
JournalEuropean Journal of Pain Supplements
Volume4
Issue number4
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Neuralgia
Analgesia
Opioid Analgesics
Viruses
Mutation
Genes
Therapeutics
Central Nervous System
Analgesics
Pain
Nociceptors
Chronic Pain
Theoretical Models

Keywords

  • Analgesia
  • Herpes simplex virus
  • Mu opioid receptor
  • Neuropathic pain

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Peripheral opioid analgesia for the treatment of neuropathic pain : Gene mutation to virus mediated gene transfer. / Sweitzer, Sarah M.; Minella, Cristina E.; Wilson, Steven P.; Raja, Srinivasa N.

In: European Journal of Pain Supplements, Vol. 4, No. 4, 11.2010, p. 251-256.

Research output: Contribution to journalArticle

Sweitzer, Sarah M. ; Minella, Cristina E. ; Wilson, Steven P. ; Raja, Srinivasa N. / Peripheral opioid analgesia for the treatment of neuropathic pain : Gene mutation to virus mediated gene transfer. In: European Journal of Pain Supplements. 2010 ; Vol. 4, No. 4. pp. 251-256.
@article{a8f8df6bd7c34b7387f9c619d60fa0d0,
title = "Peripheral opioid analgesia for the treatment of neuropathic pain: Gene mutation to virus mediated gene transfer",
abstract = "Neuropathic pain can result from a number of different diseases, medical interventions and injuries. In addition to varying aetiologies, neuropathic pain may also differ in the anatomical location of the lesion - from peripheral nociceptors to the highest centres in the brain. The management of neuropathic pain continues to be a challenge for clinicians and despite taking prescribed medication for pain, patients with neuropathic pain continue to have pain of moderate severity. The use of opioids for the treatment of chronic neuropathic pain remains controversial. Recent studies demonstrate opioid analgesics are effective in neuropathic pain states but their use is often limited by unacceptable side effects that are mediated by opioid actions in the central nervous system. While it was once dogma that opioids exert their analgesic effects by binding to receptors in the central nervous system, there is a growing recognition of a potent peripheral analgesia in experimental models of inflammatory and neuropathic pains, and in clinical settings. The working model is that peripheral opioids can be used to treat neuropathic pain while avoiding the often dose-limiting and unacceptable central nervous system mediated side effects. Our work has focused on characterizing this peripheral opioid analgesia such that it can be exploited to develop novel and potent peripheral analgesics for the treatment of neuropathic pain. This article will set the clinical stage for the need for novel treatments for neuropathic pain, the use of gene mutation strategies to make the case for the use of opioids in treating neuropathic pain, the demonstration of peripheral opioid analgesia in neuropathic pain, and our work with virus mediated gene transfer to enhance peripheral opioid analgesia in neuropathic pain.",
keywords = "Analgesia, Herpes simplex virus, Mu opioid receptor, Neuropathic pain",
author = "Sweitzer, {Sarah M.} and Minella, {Cristina E.} and Wilson, {Steven P.} and Raja, {Srinivasa N.}",
year = "2010",
month = "11",
doi = "10.1016/j.eujps.2010.09.013",
language = "English",
volume = "4",
pages = "251--256",
journal = "European Journal of Pain Supplements",
issn = "1754-3207",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Peripheral opioid analgesia for the treatment of neuropathic pain

T2 - Gene mutation to virus mediated gene transfer

AU - Sweitzer, Sarah M.

AU - Minella, Cristina E.

AU - Wilson, Steven P.

AU - Raja, Srinivasa N.

PY - 2010/11

Y1 - 2010/11

N2 - Neuropathic pain can result from a number of different diseases, medical interventions and injuries. In addition to varying aetiologies, neuropathic pain may also differ in the anatomical location of the lesion - from peripheral nociceptors to the highest centres in the brain. The management of neuropathic pain continues to be a challenge for clinicians and despite taking prescribed medication for pain, patients with neuropathic pain continue to have pain of moderate severity. The use of opioids for the treatment of chronic neuropathic pain remains controversial. Recent studies demonstrate opioid analgesics are effective in neuropathic pain states but their use is often limited by unacceptable side effects that are mediated by opioid actions in the central nervous system. While it was once dogma that opioids exert their analgesic effects by binding to receptors in the central nervous system, there is a growing recognition of a potent peripheral analgesia in experimental models of inflammatory and neuropathic pains, and in clinical settings. The working model is that peripheral opioids can be used to treat neuropathic pain while avoiding the often dose-limiting and unacceptable central nervous system mediated side effects. Our work has focused on characterizing this peripheral opioid analgesia such that it can be exploited to develop novel and potent peripheral analgesics for the treatment of neuropathic pain. This article will set the clinical stage for the need for novel treatments for neuropathic pain, the use of gene mutation strategies to make the case for the use of opioids in treating neuropathic pain, the demonstration of peripheral opioid analgesia in neuropathic pain, and our work with virus mediated gene transfer to enhance peripheral opioid analgesia in neuropathic pain.

AB - Neuropathic pain can result from a number of different diseases, medical interventions and injuries. In addition to varying aetiologies, neuropathic pain may also differ in the anatomical location of the lesion - from peripheral nociceptors to the highest centres in the brain. The management of neuropathic pain continues to be a challenge for clinicians and despite taking prescribed medication for pain, patients with neuropathic pain continue to have pain of moderate severity. The use of opioids for the treatment of chronic neuropathic pain remains controversial. Recent studies demonstrate opioid analgesics are effective in neuropathic pain states but their use is often limited by unacceptable side effects that are mediated by opioid actions in the central nervous system. While it was once dogma that opioids exert their analgesic effects by binding to receptors in the central nervous system, there is a growing recognition of a potent peripheral analgesia in experimental models of inflammatory and neuropathic pains, and in clinical settings. The working model is that peripheral opioids can be used to treat neuropathic pain while avoiding the often dose-limiting and unacceptable central nervous system mediated side effects. Our work has focused on characterizing this peripheral opioid analgesia such that it can be exploited to develop novel and potent peripheral analgesics for the treatment of neuropathic pain. This article will set the clinical stage for the need for novel treatments for neuropathic pain, the use of gene mutation strategies to make the case for the use of opioids in treating neuropathic pain, the demonstration of peripheral opioid analgesia in neuropathic pain, and our work with virus mediated gene transfer to enhance peripheral opioid analgesia in neuropathic pain.

KW - Analgesia

KW - Herpes simplex virus

KW - Mu opioid receptor

KW - Neuropathic pain

UR - http://www.scopus.com/inward/record.url?scp=78149360825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149360825&partnerID=8YFLogxK

U2 - 10.1016/j.eujps.2010.09.013

DO - 10.1016/j.eujps.2010.09.013

M3 - Article

AN - SCOPUS:78149360825

VL - 4

SP - 251

EP - 256

JO - European Journal of Pain Supplements

JF - European Journal of Pain Supplements

SN - 1754-3207

IS - 4

ER -